The direct-to-consumer at-home health testing firm intends to use the funds to expands its platform development and supply logistics in North America.
Elucigene has been developing in vitro diagnostics for oncology and reproductive health, including tests for cystic fibrosis screening and prenatal fetal aneuploidy screening.
The new assay is part of the company's prenatal and women's health offerings, but it is also developing a preeclampsia test and technology for gastrointestinal testing.
To help fund the acquisition, Yourgene Health is planning to sell at least £10.0 million in newly issued shares to institutional investors.
The Austin, Texas-based company offers more than 30 tests, including those for food sensitivity, fertility and women's hormones, sexually transmitted diseases, and thyroid.
The companies will combine their respective technologies to develop mass spectrometry-based proteomics assays for adverse pregnancy outcomes.
Yikon's test uses next-generation sequencing to screen embryos for chromosomal aneuploidy prior to implantation and does not require a biopsy.
The company said its higher revenues were due in part to international performance including continued penetration of Middle Eastern and Asian markets.
A study of 10 commercial labs offering NIPT in the US found that none followed all recommendations for reporting results and informing patients and providers.
The company will use the money to launch its first product, Unity, a noninvasive prenatal test for recessively inherited single-gene disorders.
The addition of the Y chromosome detection will enable the firm to refine its already-approved MaternalFetalScreen T1 test to provide personalized risk assessment.
An assay based on a simple dye-protein interaction is now in clinical trials, with recent research suggesting it can accurately detect preeclampsia.
Under a proposed decision, to be finalized in August and become effective in late 2020, NIPT would only be covered for women with particular fetal trisomy risks.
The company will launch a clinical version of its liquid biopsy assay in the second quarter and plans to launch clinical trials that make the case for reimbursement.
The company ran 668,600 tests during the year, a 30 percent increase from its 2017 testing volume.
Using BGI's sequencing technology, the firms plan to commercialize Natera's Signatera test in China and to develop reproductive health tests in "select markets."
The firm has launched a 2,300-subject prospective study evaluating the test, which measures exosome proteins to assess a woman's risk of preterm delivery.
The team found that patients with a threshold of 100 micromoles of bile acid per liter were as much as twice as likely to have stillbirths as other groups.
Last week, Invitae launched its Non-Invasive Prenatal Screening test while Myriad expanded its Prequel Prenatal Screen to cover all aneuploidies.
The new channel, to be launched in the second quarter, is part of the company's plan to make genetic testing affordable and accessible to everyone.